Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 27:12:32.
doi: 10.1186/s13223-016-0138-9. eCollection 2016.

Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization

Stephen D Betschel  1 , Richard J Warrington  2 , Robert Schellenberg  3
Affiliations
Review

Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization

Stephen D Betschel et al. Allergy Asthma Clin Immunol. .

Abstract

In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A total of 135 patients were treated with Octagam(®), for conditions represented by five distinct indication groups. The results of this review indicate that Octagam(®) has been well adopted and is prescribed to Canadian patients similar to other IVIg products. In alignment with current practices, 85 % of Octagam's utilization was classified as appropriate based on Canadian IVIg guidelines.

Keywords: IVIg; Indication; Octagam®.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage of patients treated with Octagam® 10 % by indication category
Fig. 2
Fig. 2
Comparison of the ORBCoN audit findings for IVIg utilization in Ontario to Octagam® utilization across three Canadian Institutions highlighting labeled, off-label and potentially indicated, versus off-label and not indicated usage
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255(Suppl 3):3–6. doi: 10.1007/s00415-008-3002-0. - DOI - PubMed
    1. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008;28(4):737–764, viii. doi: 10.1016/j.iac.2008.06.004. - DOI - PubMed
    1. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728. - PubMed
    1. Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979;36(2):237–243. - PMC - PubMed
    1. Roifman CM, Lederman HM, Lavi S, Stein LD, Levison H, Gelfand EW. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985;79(2):171–174. doi: 10.1016/0002-9343(85)90006-3. - DOI - PubMed

LinkOut - more resources